
Opinion|Videos|July 2, 2024
Examining 3-Year Update Data from the CASPIAN Trial
A medical expert discusses the impact of the 3-year overall survival data from the CASPIAN trial on the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC), emphasizing the significance of the long-term follow-up results in shaping the current treatment paradigm.
Advertisement
Episodes in this series

- Please review the 3-year overall survival update from the CASPIAN trial, assessing durvalumab ± tremelimumab plus platinum-etoposide in the first-line treatment of ES-SCLC, and discuss the impact of these findings on the treatment landscape. (
Paz-Ares L, et al. ESMO Open. 2022: 7(2):100408 )
- Please comment on how clinical outcomes from this trial have influenced the treatment algorithm for ES-SCLC and the importance of the long-term follow-up data.
- From a clinical perspective, how impactful to you and to your patients with ES-SCLC is the survival rate, which tripled from 6% to 18% at 3 years in the CASPIAN clinical trial?
- With the updated CASPIAN trial outcomes and the endpoints from ADRIATIC, can we now extrapolate the survival benefits with immunotherapy, which apply to all stages of SCLC?
- In the exploratory analysis of the CASPIAN Phase III clinical trial, a similar prevalence of neuroendocrine and non-neuroendocrine subtypes was detected in a subgroup of 104 patients with RNA sequencing data. However, Inflamed or YAP1 subtypes in the durvalumab + etoposide treatment arm experienced the longest overall survival.
- What characteristics of these SCLC subtypes suggest that they may be betterprimed to respond to immunotherapy, and what are some future clinical implications of this finding?
Advertisement
Related to this article

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

